Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.

KITE-753 is to enter pivotal development – head-to-head against Yescarta.

Circle Pharma and Verismo feature in coveted sessions.

A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.

The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.

Talapro-3 could help move Talzenna into earlier prostate cancer.